Niraparib
Ovarian Neoplasms
GlaxoSmithKlineSmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 73/ 100
Competitive context
78 Active assets in the Ovarian Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 GlaxoSmithKline | Phase 4 | BBB |
Carboplatin Eli Lilly and Company | Phase 3 | BB |
gw786034 The Christie NHS Foundation Trust | Phase 2 | BB |
tlk286 Telik | Phase 3 | BB |
Docetaxel Merck Sharp & Dohme LLC | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Niraparib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →